The main pharmacological action is to relax vascular smooth muscle. Nitroglycerin releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle and other tissues, leading to dephosphorylation of myosin light chain, regulating the contraction state of smooth muscle, and causing vasodilation. Nitroglycerin dilates the arteriovenous vascular bed, mainly dilating the veins, and its intensity is dose-related. Peripheral vein dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart and reducing the left ventricular end-diastolic pressure (preload). Dilation of arteries reduces peripheral resistance (afterload). Arteriovenous dilation reduces myocardial oxygen consumption and relieves angina pectoris. It also has a dilating effect on epicardial coronary artery branches. Therapeutic doses can reduce systolic blood pressure, diastolic blood pressure and mean arterial pressure, and effective coronary perfusion pressure can often be maintained, but when blood pressure is excessively reduced or heart rate increases, shortening the diastolic filling time, effective coronary perfusion pressure is reduced. It reduces the increased central venous pressure, pulmonary capillary wedge pressure, pulmonary vascular resistance and systemic vascular resistance. The heart rate usually increases slightly, which is probably a reflex effect of the decrease in blood pressure. The cardiac index may increase, decrease or remain unchanged. In patients with increased left ventricular filling pressure and peripheral resistance and low cardiac index, the cardiac index may increase. On the contrary, in patients with normal left ventricular filling pressure and cardiac index, intravenous medication can slightly reduce the cardiac index.

The main pharmacological action is to relax vascular smooth muscle. Nitroglycerin releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle and other tissues, leading to dephosphorylation of myosin light chain, regulating the contractile state of smooth muscle, and causing vasodilation.

The main pharmacological action is to relax vascular smooth muscle. Nitroglycerin releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle and other tissues, leading to dephosphorylation of myosin light chain, regulating the contractile state of smooth muscle, and causing vasodilation.

This product is an organic iodide, an auxiliary therapeutic drug that promotes the absorption of pathological turbidity. It is absorbed slowly after injection, and most of it exists in adipose tissue and nerve tissue. It gradually decomposes into free iodine in the body and distributes throughout the body. It can promote the absorption of inflammatory exudates and other pathological deposits in tissues and the dissipation of chronic inflammation.

It changes the signal transmission of the central nervous system, has an stimulatory effect on dopamine receptors and 5-hydroxytryptamine receptors, and a blocking effect on α-adrenergic receptors; it improves the damaged brain metabolic function and shortens the cerebral circulation time; it improves the symptoms of intellectual decline (especially age-related intellectual decline), stabilizes cerebral vascular tension, and prevents migraines.

As a component of dihydroergotamine mesylate, it participates in the above-mentioned pharmacological actions.

As a component of dihydroergotamine mesylate, it participates in the above-mentioned pharmacological actions.

As one of the isomers of dihydroergocryptine mesylate, it participates in the above-mentioned pharmacological effects.

As one of the isomers of dihydroergocryptine mesylate, it participates in the above-mentioned pharmacological effects.

As a component of dihydroergotamine mesylate, it participates in the above-mentioned pharmacological actions.